-
9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one
-
ChemBase ID:
4388
-
Molecular Formular:
C19H27NO3
-
Molecular Mass:
317.42258
-
Monoisotopic Mass:
317.19909373
-
SMILES and InChIs
SMILES:
O=C1C(CN2C(C1)c1c(CC2)cc(OC)c(OC)c1)CC(C)C
Canonical SMILES:
COc1cc2c(cc1OC)CCN1C2CC(=O)C(C1)CC(C)C
InChI:
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
InChIKey:
MKJIEFSOBYUXJB-UHFFFAOYSA-N
-
Cite this record
CBID:4388 http://www.chembase.cn/molecule-4388.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Nitoman
|
Regulin
|
Rubigen
|
Xenazine
|
|
|
Synonyms
|
Tetra benazin
|
Tetrabenazina [inn-spanish]
|
Tetrabenazinum [inn-latin]
|
Tetrabenzaine
|
Tetrabenzine
|
Tetrabenazine
|
(3R,11bR)-rel-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one
|
cis-2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine
|
(+/-)-Tetrabenazine
|
NSC 169886
|
NSC 172187
|
Ro 1-9569
|
Rubigen
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
TRC
|
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
18.239992
|
H Acceptors
|
4
|
H Donor
|
0
|
LogD (pH = 5.5)
|
1.4955962
|
LogD (pH = 7.4)
|
3.094543
|
Log P
|
3.4010618
|
Molar Refractivity
|
91.3074 cm3
|
Polarizability
|
35.678963 Å3
|
Polar Surface Area
|
38.77 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
Log P
|
3.23
|
LOG S
|
-2.94
|
Solubility (Water)
|
3.61e-01 g/l
|
DETAILS
DETAILS
DrugBank
TRC
DrugBank -
DB04844
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A drug formerly used as an antipsychotic but now used primarily in the treatment of various movement disorders including tardive dyskinesia. Tetrabenazine blocks uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system. [PubChem] |
Indication |
For the symptomatical treatment of hyperkinetic movement disorder. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
CYP2D6 mediated hepatic metabolism. |
Protein Binding |
82-85% |
Elimination |
After oral administration, tetrabenazine is extensively hepatically metabolized, and the metabolites are primarily renally eliminated. In a mass balance study in 6 healthy volunteers, approximately 75% of the dose was excreted in the urine and fecal recovery accounted for approximately 7-16% of the dose. Urinary excretion of α-HTBZ or β-HTBZ (the major metabolites)accounted for less than 10% of the administered dose. |
Clearance |
Tetrabenazine is cleared renally and fecally. |
References |
• |
Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb;48(2):358-62.
[Pubmed]
|
|
External Links |
|
|
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb;48(2):358-62. Pubmed
- • Schwartz, et al.: Biochem. Pharmacol., 15, 645 (1966)
- • Janovic, J., et al.: Ann. Neurol., 11, 41 (1966)
- • Janovic, J., et al.: Neurology, 38, 391 (1966)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent